LakeShore Biopharma Co., Ltd
LSBNASDAQHealthcare
$0.63
+$0.00(+0.00%)
Market Cap$25840359
P/E Ratio—
52W High$8.6
52W Low$0.574
LakeShore Biopharma Co., Ltd (LSB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LSB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: Apr 18, 2025EPS Actual
-$1.20
Est. -$0.60 · -100.0%
Revenue
—
Fiscal Period
Q2 FY2025
FY ends December
Report Date
Apr 18, 2025
After Market Close
▼ Miss EPS
LSB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2025 | Jul 31, 2025 | -$0.17 | — | — | — | $0.03B | — |
| ▼ Q2 FY2025 | Apr 18, 2025 | -$0.60 | -$1.20 | -100.0% | — | — | — |
| ▼ Q1 FY2025 | Jan 27, 2025 | -$0.80 | -$1.60 | -100.0% | — | — | — |
| ◌ Q4 FY2024 | Dec 19, 2024 | -$5.50 | — | — | — | — | — |
| ▼ Q3 FY2024 | Sep 24, 2024 | -$0.58 | -$1.34 | -131.0% | — | $0.02B | — |
| ▼ Q2 FY2024 | Apr 19, 2024 | -$0.09 | -$0.12 | -33.3% | $0.14B | $0.02B | +574.0% |
| — Q4 FY2023 | Dec 30, 2023 | — | -$0.86 | — | $0.17B | — | — |
| — Q3 FY2023 | Sep 30, 2023 | — | -$1.13 | — | $0.10B | — | — |
Q3 FY2025
Jul 31, 2025
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 18, 2025Miss
EPS Actual
-$1.20
EPS Est.
-$0.60
EPS Surpr.
-100.0%
Revenue
—
Q1 FY2025
Jan 27, 2025Miss
EPS Actual
-$1.60
EPS Est.
-$0.80
EPS Surpr.
-100.0%
Revenue
—
Q4 FY2024
Dec 19, 2024
EPS Actual
—
EPS Est.
-$5.50
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 24, 2024Miss
EPS Actual
-$1.34
EPS Est.
-$0.58
EPS Surpr.
-131.0%
Revenue
—
Q2 FY2024
Apr 19, 2024Miss
EPS Actual
-$0.12
EPS Est.
-$0.09
EPS Surpr.
-33.3%
Revenue
$0.14B
Q4 FY2023
Dec 30, 2023
EPS Actual
-$0.86
EPS Est.
—
EPS Surpr.
—
Revenue
$0.17B
Q3 FY2023
Sep 30, 2023
EPS Actual
-$1.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.10B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q4 FY2024 | $-4.30 | $-4.30 | $-4.30 | 1 |
| Q3 FY2024 | $-5.50 | $-5.50 | $-5.50 | 1 |
| Q2 FY2024 | $-6.80 | $-6.80 | $-6.80 | 1 |
| Q1 FY2024 | $-5.81 | $-5.81 | $-5.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2025 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2024 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2024 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2024 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2024 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2025 | Apr 18, 2025 | -100.0% | $1.38 | $1.28 | -7.25% |
| ▼ Q1 FY2025 | Jan 27, 2025 | -100.0% | $2.62 | $2.75 | +4.96% |
| ▼ Q3 FY2024 | Sep 24, 2024 | -131.0% | $7.71 | $7.68 | -0.39% |
| ▼ Q2 FY2024 | Apr 19, 2024 | -33.3% | $8.55 | $7.25 | -15.20% |
| — Q4 FY2023 | Dec 30, 2023 | — | $5.11 | $5.10 | -0.20% |
| — Q3 FY2023 | Sep 30, 2023 | — | $8.00 | $7.53 | -5.87% |
| — Q2 FY2023 | Jun 30, 2023 | — | $14.00 | $13.80 | -1.43% |
| — Q1 FY2023 | Mar 31, 2023 | — | $20.40 | $16.00 | -21.57% |
Q2 FY2025-7.25%
Report Date
Apr 18, 2025
EPS Beat/Miss
-100.0%
Price Before
$1.38
Price After
$1.28
Q1 FY2025+4.96%
Report Date
Jan 27, 2025
EPS Beat/Miss
-100.0%
Price Before
$2.62
Price After
$2.75
Q3 FY2024-0.39%
Report Date
Sep 24, 2024
EPS Beat/Miss
-131.0%
Price Before
$7.71
Price After
$7.68
Q2 FY2024-15.20%
Report Date
Apr 19, 2024
EPS Beat/Miss
-33.3%
Price Before
$8.55
Price After
$7.25
Q4 FY2023-0.20%
Report Date
Dec 30, 2023
EPS Beat/Miss
—
Price Before
$5.11
Price After
$5.10
Q3 FY2023-5.87%
Report Date
Sep 30, 2023
EPS Beat/Miss
—
Price Before
$8.00
Price After
$7.53
Q2 FY2023-1.43%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$14.00
Price After
$13.80
Q1 FY2023-21.57%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$20.40
Price After
$16.00
Avg Miss Reaction-4.47%
Beat Rate0 / 8 quarters
Largest Move-21.57% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LSB ends December
LakeShore Biopharma Co., Ltd (LSB) most recently reported earnings on April 18, 2025 for Q2 FY2025, posting EPS of $-1.20 — missing the analyst consensus of $-0.60 by -100.0%. The next LSB earnings date is expected around September 1, 2026.
Each quarter, investors track LSB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LSB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LSB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LSB earnings · 5 questionsLakeShore Biopharma Co., Ltd's next earnings report is expected around September 1, 2026. LSB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LSB historically reports after market close (AMC).
LSB earnings datewhen is LSB earningsLSB next earnings datewhen does LSB report earningsLSB earnings calendar
▸ Source: FMP · LakeShore Biopharma Co., Ltd SEC filings · US GAAP · LakeShore Biopharma Co., Ltd SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026